Corticosteroid-sparing agents: Conventional systemic immunosuppressants

Developments in Ophthalmology

Volumn 51, Issue , 2012, Pages 29-46

  Kruh, Jonathan ^a   Foster, C Stephen ^a  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; ARTICLE; CELLULAR IMMUNITY; DRUG COMBINATION; DRUG EFFECT; EYE DISEASE; HUMAN; IMMUNOLOGY;

ANIMALS; DRUG THERAPY, COMBINATION; EYE DISEASES; GLUCOCORTICOIDS; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS;

EID: 84860851013     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000336185     Document Type: Article

References (138)

1. Dorr R, Fritz W: Cancer Chemotherapy Handbook. Amsterdam, Elsevier, 1980.
2. Krumbhaar EB, Krumbhaar HD: The blood and bone marrow in yellow cross gas (mustard gas) poisoning: changes produced in the bone marrow of fatal cases. J Med Res 1919;40:497-507.
3. Gery I, Nussenblatt RB: Immunosuppressive drugs; in Sears ML (eds): Pharmacology of the Eye. Berlin, Springer, 1984, pp 586-609.
4. Roda-Perez E: Sobre un case se uveitis de etiologia ignota tratado con mostaza introgenada. Rev Clin Esp 1951;40:265-267.
5. Roda-Perez E: El tratamiento de las uveitis de etiologia ignota con mostaza nitrogenada. Arch Soc Ofial Hisp Am 1952;12:131-151.
6. Brock N: Oxazaphosphorine cytostatics: pastpresent-future: Seventh Cain Memorial Award Lecture. Cancer Res 1989;49:1-7. (Pubitemid 19024399)
7. Calabresi P, Chabner BA: Chemotherapy of neoplastic diseases; in Gilman AG, Rall TW, Nies AS, Taylor P (eds): Goodman and Gilman's the Pharmacological Basis of Therapeutics. New York, Pergamon Press, 1990, pp 1202-1263.
8. Foster CS: Pharmacologic treatment of immune disorders; in Albert DM, Jakobiec FA (eds): Principles and Practice of Ophthalmology, Basic Sciences. Philadelphia, WB Saunders, 1994, pp 1076-1084.
9. Stockman GP, Heim LR, South MA, Trentin JJ: Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol 1973;110:277-282.
10. Clements PJ, Yu DTY, Levy J, Paulus HE, Barnett EU: Effects of cyclophosphamide on B and T lymphocytes in rheumatoid arthritis. Arthritis Rheum 1974;17:347-353.
11. Fauci AS, Date DC, Wolff SM: Cyclophosphamide and lymphocyte subpopulations in Wegener's granulomatosis. Arthritis Rheum 1974;17:355-361.
12. Lerman SP, Weidanz WP: The effect of cyclophosphamide on the ontogeny of the humoral immune response in chickens. J Immunol 1970;105:614-619.
13. Hemady R, Tauber J, Foster CS: Immunosuppressive drugs in immune and inflammatory disease. Surv Ophthalmol 1991:35:359-385.
14. Brubaker R, Font RL, Shepero EM: Granulomatous sclerouveitis, regression of ocular lesions with cyclophosphamide and prednisone. Arch Ophthalmol 1971;86:517-524.
15. Foster CS: Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology 1980; 87:140-150.
16. Jampol LM, West C, Goldberg MF: Therapy of scleritis with cytotoxic agents. Am J Ophthalmol 1978;86:266-271. (Pubitemid 8380873)
17. Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener's granulomatosis: prospective clinical and therapeutic experience with patients for years. Ann Intern Med 1983;98:75-85.
18. Foster CS: Systemic immunosuppressive therapy for progressive bilateral Mooren's ulcer. Ophthalmology 1985,92:1436-1439. (Pubitemid 16228038)
19. Brown SI, Mondino BJ: Therapy of Mooren's ulcer. Am J Ophthalmol 1984;98:1-6. (Pubitemid 14089526)
20. Foster CS: Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986;84:527-663. (Pubitemid 17110250)
21. Oniki S, Kurakazu K, Kawata K: Immunosuppressive treatment of Behcet's disease with cyclophosphamide. Jpn J Ophthalmol 1976;20:32-40.
22. Fain O, Du LTH, Wechsler B: Pulse cyclophosphamide in Behçet's disease; in: O'Duffy JD, Kokmen E (eds): Behçet's Disease: Basic and Clinical Aspects. New York: Marcel Dekker, 1991, pp 569-573.
23. Buckley CE, Durham NC, Gills JP: Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med 1969;124:29-35.
24. Martenet AC: Immunosuppressive therapy of uveitis: mid-and long-term follow up after classical cytostatic treatment; in Usui M, Ohno S, Aoki K (eds): Ocular Immunology Today. New York: Excerpta Medica, 1990, pp 443-446.
25. Rapini RP, Jordan RE, Wolverton SE: Cytotoxic agents; in Wolverton SE, Wilkins JK (eds): Systemic Drugs for Skin Diseases. Philadelphia: WB Saunders, 1991, pp 125-151.
26. AMA drug evaluations. Chicago, American Medical Association, 1991, pp 396, 1059, 1654-1655, 1671-1672, 1843-1844, 1972-1973, 1891-1913, 2009-2034, 2140-2141, 2351-2353
27. Fairley KF, Barrie JV, Johnson W: Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet 1972;1:568-569.
28. Berkson BM, Come LG, Shapiro I: Severe cystitis induced by cyclophosphamide, role of surgical management. JAMA 1973;225:605-606.
29. Fraunfelder FT, Meyer SM: Ocular toxicity from antineoplastic agents. Ophthalmology 1983;90:1-3.
30. Puri HC, Campbell RA: Cyclophosphamide and malignancy. Lancet 1977;1:1306. (Pubitemid 8130991)
31. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA Jr: Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 1987;83:1-9. (Pubitemid 18099020)
32. Baltus JA, Boersma JW, Hartman AP, Vandenbroucke JP: The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 1983;42:368-373. (Pubitemid 13037092)
33. Kempen JH, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT: Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 2008;146:802-812.
34. Mamo JG, Azzam SA: Treatment of Behcet's disease with chlorambucil. Arch Ophthalmol 1970;84: 446-450.
35. Rubin B, Palestine AG: Complications of corticosteroids and immunosuppressive drugs. Int Ophthalmol Clin 1989;29:159-169.
36. Ben Ezra D, Cohen E: Treatment and visual prognosis in Behcet's disease. Br J Ophthalmol 1986;70:589-592. (Pubitemid 16038279)
37. Bietti GB, Ceruili L, Pivetti-Pezzi P: Behcet's disease and immunosuppressive treatment. Mod Probl Ophthalmol 1976;16:314-323.
38. O'Duffy JD, Robertson DM, Goldstein NP: Chlor ambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med 1984;76:75-84. (Pubitemid 14216363)
39. Pezzi PD, Gaspani U, DeLiso P, Catarinelli G: Prognosis in Behcet's disease. Ann Ophthalmol 1985;17:20-25. (Pubitemid 15127694)
40. Tricoulis D: Treatment of Behcet's disease with chlorambucil. Br J Ophthalmol 1976;60:55-57.
41. Abdalla MI, Bahgat N: Long-lasting remission of Behcet's disease after chlorambucil therapy. Br J Ophthalmol 1993;57:706-710.
42. Elliot JH, Ballinger WH: Behcet's syndrome. Treatment with chlorambucil. Trans Am Ophthalmol Soc 1984;82:264-281.
43. Godfrey WA, Epstein WV, O'Connor GR, et al.: The use of chlorambucil in intractable idiopathic uveitis. Am J Ophthalmol 1974;78:415-428.
44. Kanski JJ: Anterior uveitis in juvenile rheumatoid arthritis. Arch Ophthalmol 1977;95:1794-1797. (Pubitemid 8205924)
45. Foster CS, Barrett F: Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis-associated iridocyclitis. Ophthalmology 1993;100:809-817. (Pubitemid 23163490)
46. Jennings T, Tessler HH: Twenty cases of sympathetic ophthalmia. Br J Ophthalmol 1989;73:140-145. (Pubitemid 19056448)
47. Clements PJ, Davis J: Cytotoxic drugs: Their clinical application to the rheumatic diseases. Semin Arthritis Rheum 1986;15:231-254. (Pubitemid 16024339)
48. Tabbara KF: Chlorambucil in Behcet's disease, a reappraisal. Ophthalmology 1983;90:906-908.
49. Williams SA, Makker SP, Grupe WE: Seizures, a significant side effect of chlorambucil therapy in children. J Pediatr 1978;93:510-518.
50. Kempen JH, Daniel E, Dunn JP, Foster CS, Gangaputra S, Hanish A, Helzlsouer KJ, Jabs DA, Kaçmaz RO, Levy-Clarke GA, Liesegang TL, Newcomb CW, Nussenblatt RB, Pujari SS, Rosenbaum JT, Suhler EB, Thorne JE: Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480.
51. Kempen JH, Daniel E, Gangaputra S, Dreger K, Jabs DA, Kacmaz RO: Methods for identifying longterm adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) cohort study. Ophthalmic Epidemiol 2008;15:47-55. (Pubitemid 351311499)
52. Berk PA, Goldberg JD, Silverman MN, et al.: Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981;304:441-447. (Pubitemid 11178999)
53. Lemer HJ: Acute myelogenous leukemia in students receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer. Cancer Treat Rep 1978;62:1135-1138.
54. Smith AL (ed): Oxford Dictionary of Biochemistry and Molecular Biology. Oxford: Oxford University Press, pp 43.
55. Farber S, Diamond LK, Mercer RD: Temporary remissions in acute leukemia in children produced by folic antagonist 4-amethopteroylglutamic acid (aminopterin). N Engl J Med 1948;238:787-793.
56. Weinblatt ME, Kremer JM: Methotrexate in rheumatoid arthritis. J Am Acad Dermatol 1988;19: 126-128.
57. Lally EV, Ho G: A review of methotrexate therapy in Reiter's syndrome. Semin Arthritis Rheum 1985;15: 139-145. (Pubitemid 16215433)
58. Wong VG, Hersh EM: Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol 1965;69:279-293.
59. Callen JP, Kulp-Shorten CL: Methotrexate; in Wolverton SE, Wilkins JK (eds): Systemic Drugs for Skin Diseases. Philadelphia: WB Saunders, 1991, pp 152-166.
60. Andersen PA, West SG, O'Dell JR: Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985;103:489-496.
61. Weinblatt ME, Coblyn JS, Fox DA: Efficacy of lowdose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-822. (Pubitemid 15104774)
62. Shah SS, Lowder CY, Schmidt MA, et al.: Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992;99:1419-1423.
63. Wong VG: Methotrexate treatment of uveal disease. Am J Med Sci 1966;251:239-241.
64. Wong VG, Hersh EM, McMaster PRB: Treatment of a presumed case of sympathetic ophthalmia with methotrexate. Arch Ophthalmol 1966;76:66-76.
65. Walker AM, Funch D, Dreyer NA: Determinants of serious liver disease among patients receiving lowdose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993;36:329-335. (Pubitemid 23090599)
66. Huang-Xuan T, Foster CS, Rice BA: Scleritis in relapsing polychondritis: response to therapy. Ophthalmology 1990;97:892-898. (Pubitemid 20217939)
67. Dev S, McCallum RM, Jaffee GJ: Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999;106:111.
68. Olsen EA: The pharmacology of methotrexate. J Am Acad Dermatol 1991;25:306-317.
69. Shupack JL, Webster OF: Pancytopenia following low-dose oral methotrexate therapy for psoriasis. JAMA 1988;259:3594-3596.
70. Ridley MG, Wolfe CS, Mathews JH: Life-threatening acute pneumonitis during low-dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature. Ann Rheum Dis 1988; 47:784-788.
71. Schein PS, Winokur SH: Immunosuppressive and cytotoxic chemotherapy: long-term complications. Ann Intern Med 1975;82:94-95.
72. Bailin PL, Tindall JP, Roenigk HH Jr, Hogan MD: Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. JAMA 1975;232:359-362.
73. Nyfors A, Jensen H: Frequency of malignant neoplasms in long-term methotrexate- treated psoriatics. A preliminary study. Dermatologica 1983; 167:260-261. (Pubitemid 14239780)
74. Wolfe F, Michaud K: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, patients during 89, person-years of observation. Arthritis Rheum 2007;56:1433-1439. (Pubitemid 46764070)
75. Tishler M, Caspi D, Yaron M: Long-term experience with low-dose methotrexate in rheumatoid arthritis. Rheumatol Int 1993;13:103-106. (Pubitemid 23306536)
76. Georgescu L, Quinn GC, Schwartzman S, Paget SA: Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997;26:794-804. (Pubitemid 27274443)
77. Newell FW, Krill AE: Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK 1967;87:499-511.
78. Newell FW, Krill AE, Thompson A: The treatment of uveitis with six-mercaptopurine. Am J Ophthalmol 1966;61:1250-1255.
79. Bach JH: The Mode of Action of Immunosuppressive Drugs. Amsterdam, Elsevier, 1975.
80. Hemady R, Baer JC, Foster CS: Immunosuppressive drugs in the management of progressive, corticosteroid-resistant uveitis associated with juvenile rheumatoid arthritis. Int Ophthalmol Clin 1992;32:241-252.
81. Yazici H, Pazarli H, Bames CG: A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990;322:281-285. (Pubitemid 20046329)
82. Foster CS, Baer JC, Raizman MB: Therapeutic responses to systemic immunosuppressive chemotherapy agents in patients with Behcet's syndrome affecting the eyes; in O'Duffy JD, Kokmen E (eds): Behcet's Disease: Basic and Clinical Aspects. New York: Marcel Dekker, 1991, pp 581-588.
83. Pavan-Langston D, Dunkel EC: Handbook of Ocular Drug Therapy and Ocular Side Effects of Systemic Drugs. Boston, Little, Brown, 1991, pp 203-213.
84. Nussenblatt RB, Palestine AG: Uveitis, Fundamentals and Clinical Practice. Chicago: Year Book Medical Publishers, 1989, pp 116-144.
85. Singh G, Fries JF, Spitz P, Williams CA: Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 1989; 32:837-843. (Pubitemid 19181005)
86. Castor CW, Bull FE: Review of United States data on neoplasms in rheumatoid arthritis. Am J Med 1985; 78:33-38. (Pubitemid 15167363)
87. Hazleman BL: The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. Ann Rheum Dis 1982;41:12-17. (Pubitemid 12151671)
88. Fraser AG, Orchard TR, Robinson EM, Jewell DP: Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002;16:1225-1232.
89. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-1252. (Pubitemid 24158045)
90. Borel JF: The history of cyclosporin A and its significance; White DJG (eds): Cyclosporin A. New York: Elsevier, 1982, pp 5-17.
91. Heusler K, Pletscher A: The controversial early history of cyclosporine. Swiss Med Wkly 2001;131:299-302.
92. Nussenblatt RB, Palestine AG, Rook AH: Treatment of intraocular inflammation with cyclosporin A. Lancet 1983;1:235-238.
93. Nussenblatt RB, Palestine AG, Chan CC: Cyclosporine A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983;96:275-282. (Pubitemid 13000969)
94. deSmet MD, Nussenblatt RB: Clinical use of cyclosporine in ocular disease. Int Ophthalmol Clin 1993;33:31-45. (Pubitemid 23331155)
95. Sigal NH, Dumont FJ: Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 1992;10: 519-560.
96. Liu J: FK and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993;14:290-295. (Pubitemid 23186993)
97. Sigal SN: Immunosuppressive profile of rapamycin. Ann N Y Acad Sci 1993;685:1-8.
98. Chang JY, Sehgal SN: Pharmacology of rapamycin: a new immunosuppressive agent. B J Rheumatol 1991;30(suppl 2):62-65.
99. Chang JY, Sehgal SN, Bansbach CC: FK and rapamycin: novel pharmacological probes of the immune response. Trends Pharmacol Sci 1991;12: 218-223.
100. Nussenblatt RB, Palestine AG, Chan CC, Ochizuki M, Yancey K: Effectiveness of cyclosporine therapy for Behcet's disease. Arthritis Rheum 1985;28:671-679. (Pubitemid 15059078)
101. Nussenblatt RB, Palestine AG, Chan CC: Improvement of uveitis and optic nerve disease by cyclosporine in a patient with multiple sclerosis. Am J Ophthalmol 1984;97:790-791. (Pubitemid 14082969)
102. Nussenblatt RB, Palestine AG, Chan CC: Cyclosporine therapy for uveitis: long-term follow up. J Ocul Pharmacol 1985;1:369-382. (Pubitemid 17031157)
103. Graham EM, Sanders MD, James DG, et al.: Cyclosporin A in the treatment of posterior uveitis. Trans Ophthalmol Soc UK 1985;104:146-151. (Pubitemid 15137426)
104. LeHoang P, Girard B, Deray G: Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc 1988;20(suppl 4):128-130.
105. Binder Al, Graham EM, Sanders MD: Cyclosporin A in the treatment of severe Behcet's uveitis. Br J Rheumatol 1987;76:285-291. (Pubitemid 17103851)
106. Wakefield D, McCluskey P, Reece G: Cyclosporin therapy in Vogt-Koyanagi-Harada disease. Aust N Z J Ophthalmol 1990;18:137-142.
107. Nussenblatt RB, Palestine AG, Chan CC: Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991;112:38-146.
108. Masuda K, Nakajima A, Urayama A: Doublemasked trial of cyclosporin versus colchicine and long-term open study of cyclosporine in Behcet's disease. Lancet 1989;1:1093-1096. (Pubitemid 19128039)
109. deVries J, Baarsma GS, Zaai MJW: Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 1990;74:344-349. (Pubitemid 20191166)
110. Towler HMA, Cliffe AM, Whiting PH, Forrester JV: Low dose cyclosporin A therapy in chronic posterior uveitis. Eye 1989;3:282-287. (Pubitemid 20018878)
111. Towler HMA, Whiting PH, Forrester JV: Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation. Eye 1990;4: 514-520. (Pubitemid 20274951)
112. Towler HMA, Lightman SL, Forrester JV: Low-dose cyclosporine therapy of ocular inflammation: preliminary report of a long-term follow-up study. J Autoimmun 1992;5(suppl A):259-264.
113. Vitale AT, Rodriguez A, Foster CS: Low-dose cyclosporine therapy in the treatment of birdshot retinochoroidopathy. Ophthalmology 1994;101:782-831.
114. Chavis PS, Antonios SR, Tabbara KF: Cyclosporine effects on optic nerve and retinal vasculitis in Behcet's disease. Doc Ophthalmol 1992;80:133-142.
115. Hill JC: The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 1989;107:506-510. (Pubitemid 19136623)
116. Miller K, Huber C, Niederwieser D, Gottinger W: Successful engraftment of high-risk corneal allografts with short-term immunosuppression with cyclosporine. Transplantation 1988;45:651-653. (Pubitemid 18086579)
117. Hoffman F, Widerholt M: Local treatment of necrotizing scleritis with cyclosporin A. Cornea 1985;4: 3-7.
118. Wiebking WJ, Mehlfeld T: Local treatment of corneal ulcers and scleromalacias with cyclosporin A. Fortschr Ophthalmol 1986;83:345-347. (Pubitemid 16000063)
119. Kruit PJ, VanBalen AT, Stilma JS: Cyclosporin A treatment in two cases of corneal peripheral melting syndromes. Doc Ophthalmol 1985;59:33-39. (Pubitemid 15137501)
120. Kruit PJ: Cyclosporine A treatment in four cases with corneal melting syndrome. Transplant Proc 1988;90(suppl):170-172.
121. Holland EJ, Chan CC, Kuwabara T: Immunohistological findings and results of treatment with cyclosporine in ligneous conjunctivitis. Am J Ophthalmol 1989;107:160-166. (Pubitemid 19049843)
122. Rubin BI, Holland EJ, deSmet MD: Response of reactivated ligneous conjunctivitis to topical cyclosporine. Am J Ophthalmol 1991;112:95-96.
123. Ben Ezra D, Peter J, Brodsky M, Cohen E: Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol 1986;101: 278-282. (Pubitemid 16132651)
124. Bleik PH, Tabbara KF: Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 1991;98: 1679-1684.
125. Secchi AG, Tognon MS, Leonardi A: Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990;110:641-645.
126. Handschumacher RE: Immunosuppressive agents; in Gilman AC, Rail TW, Nies AS, Taylor P (eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: Pergamon Press, 1990, pp 1264-1276.
127. Palestine AG, Nussenblatt RE, Chan CC: Cyclosporine penetration into the anterior chamber and cerebrospinal fluid. Am J Ophthalmol 1985;99:210-211.
128. Kahan BD: Cyclosporine nephrotoxicity: pathogenesis, prophylaxis, therapy and prognosis. Am J Kidney Dis 1986;8:323-331. (Pubitemid 17235078)
129. Nussenblatt RB, de Smet MD, Rubin B: A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sightthreatening uveitis of noninfectious origin. Am J Ophthalmol 1993;115:583-591. (Pubitemid 23137641)
130. Feutren G, Mihatsch MJ: Risk factors for cyclo sporine-induced nephrotoxicity in patients with autoimmune diseases. N Engl J Med 1992;326:1654-1660.
131. de Groen PL: Cyclosporine. A review and its specific use in liver transplantation. Mayo Clin Proc 1989;64:680-689.
132. Mathews D, Mathews J, Jones NP: Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol 2010;58:55-58.
133. Palestine AG, Nussenblatt RB, Chan CC: Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med 1984;77:652-656. (Pubitemid 14047594)
134. Kahan BD: Cyclosporine. N Engl J Med 1989;321: 1725-1738.
135. Nussenblatt RB, Palestine AG: Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol 1986;31:159-169. (Pubitemid 17222027)
136. Foster CS: Nonsteroidal anti-inflammatory and immunosuppressive agents; in Lamberts DW, Potter DE (eds): Clinical Ophthalmic Pharmacology. Boston, Little, Brown, 1987, pp 181-192.
137. Van den Borne BE, Landewe RB, Houkes I, Schild F, van der Heyden PC, Hazes JM: No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1930-1937. (Pubitemid 28506681)
138. Paul CF, Ho VC, McGeown C, Christophers E, Schmidtmann B, Guillaume JC: Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120: 211-216.